Pentoxifylline and antiaggregants in recent transient ischemic attacks


Phase N/A Results

Trial Description

To study the preventive capacity of a combination of acetylsalicylic acid and dipyridamole and of pentoxifylline in the reduction of morbidity rates in patients with recent TIAs.


  • Dipyridamole (Persantine┬«)Drug
    Intervention Desc: Platelet aggregation inhibitor
  • Pentoxifylline (Trental┬«)Drug
    Intervention Desc: Vasodilator. In addition, may reduce viscosity or improve erythrocyte flexibility.

Trial Design

Randomized trial of 66 patients at 4 centers.

Patient Involvement

Patients were randomized to receive either acetylsalicylic acid and dipyridamole (1,050 mg + 150 mg/day) or pentoxifylline (1,200 mg/day). Treatment was continued and patients were followed up monthly for one year.


Type Measure Time Frame Safety Issue
Primary Recurrent ischemic event.